Notice for osimertinib mesilate (AstraZeneca Pty Ltd)
Active ingredients
osimertinib mesilate
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of adult patients with locally advanced, unresectable (Stage III) NSCLC whose tumours have activating EGFR mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.
Therapeutic area
Oncology